Revvity Cut Its 2026 Outlook As It Preps A China Unit Sale

FierceBiotechAfter Arcellx buyout close, Gilead trims 108 jobs at CAR-T biotech's Redwood City outpost

FDA News ReleasesFDA Expands Market Access, Authorizes New ENDS Products

Endpoints NewsIntercept's next-gen FXR agonist fails Phase 2 in latest setback for Italian-owned pharma

Clinical OMICsMuscle Quality and Fat Distribution Predict Mortality Risk Better than BMI

Endpoints NewsPfizer's Albert Bourla says he has no mega-merger plans

Clinical OMICsGenotype-Guided Antidepressants Could Have Long-Term Benefits

ModernaBoston biotech firms back new effort to preserve U.S. edge in life sciences - The Business Journals

RevvityRevvity Outperforms in Q1 2026 Driven by Pharma Rebound and Strategic Portfolio Shifts - Lab Manager

Endpoints NewsBioNTech to scale down manufacturing, over 1,800 jobs on the line

Endpoints NewsParsley Health goes in-network nationwide

RevvityWhy Is Revvity (RVTY) Stock Rocketing Higher Today - TradingView

PfizerPfizer beats estimates but investors cautious - The Pharma Letter